| Arathi Rajendran Goldsmith, DO | |
|
835 Mason St Ste C200, Dearborn, MI 48124-2231 | |
| (313) 274-5810 | |
| (313) 274-1499 |
| Full Name | Arathi Rajendran Goldsmith |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 16 Years |
| Location | 835 Mason St Ste C200, Dearborn, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437387404 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | AG018507 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital - Dearborn | Dearborn, MI | Hospital |
| Entity Name | Michigan Center For Dermatology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053527226 PECOS PAC ID: 7315992567 Enrollment ID: O20050321000658 |
News Archive
A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the prevention of a repeated stroke.
InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.
OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arathi Rajendran Goldsmith, DO 835 Mason St, Suite C200, Dearborn, MI 48124 Ph: (313) 274-5810 | Arathi Rajendran Goldsmith, DO 835 Mason St Ste C200, Dearborn, MI 48124-2231 Ph: (313) 274-5810 |
News Archive
A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the prevention of a repeated stroke.
InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.
OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.
Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.
› Verified 6 days ago
Taylor Adlam, MD Dermatology Medicare: Medicare Enrolled Practice Location: 18100 Oakwood Blvd Ste 300, Dearborn, MI 48124 Phone: 313-240-4900 | |
Daniel J Myers, Dermatology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 800-356-7836 | |
Jennifer Heyl, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: Oakwood Hospital & Medical Center, 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 | |
Hany Deirawan, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 18100 Oakwood Blvd Ste 300, Dearborn, MI 48124 Phone: 313-240-4900 | |
Chiara Jordan Rosenbaum, DO Dermatology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-436-2581 Fax: 313-436-2071 | |
Johanna Chapel, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 2814 Monroe St, Dearborn, MI 48124 Phone: 313-561-5311 Fax: 313-561-2504 |